Analytical performance of a formalin-fixed paraffin-embedded tissue-based 634-probe prognostic assay for predicting outcome of patients with stage II colon cancer

Applied Immunohistochemistry and Molecular Morphology

Volumn 22, Issue 4, 2014, Pages 308-316

  Plamadeala, Victoria ^a   Huang, Shuguang ^a   McCreary, Suzanne M ^a   Reitze, Nicholas J ^a   Ewing, Amy L ^a   Gabrin, Michael J ^a   Bennett, Ana E ^b   Mulligan, Jude M ^c   Wilson, Claire L ^c   Wang, Dakun ^a  

^a Precision Therapeutics Inc   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

^c Almac Sciences   (United Kingdom)

Author keywords

analytical validation; formalinfixed paraffin embedded tissue based 634 probe prognostic assay; prognostic assay; stage II colon cancer

Indexed keywords

COMPLEMENTARY DNA; FORMALDEHYDE; PARAFFIN; REAGENT; RNA; DIAGNOSTIC KIT; DNA; TUMOR MARKER;

ANALYTIC METHOD; ARTICLE; CANCER PATIENT; CANCER PROGNOSIS; CANCER TISSUE; COLON CANCER; CONFIDENCE INTERVAL; DIAGNOSTIC ACCURACY; DIAGNOSTIC KIT; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE SEVERITY; DISEASE SIMULATION; EMBEDDING; FORMALIN FIXED PARAFFIN EMBEDDED TISSUE; GENE EXPRESSION; HIGH RISK PATIENT; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; LIMIT OF QUANTITATION; MAJOR CLINICAL STUDY; MOLECULAR PROBE; MULTICENTER STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUALITY CONTROL; RISK FACTOR; SENSITIVITY AND SPECIFICITY; TISSUE MICROARRAY; TISSUE SECTION; CANCER STAGING; COLONIC NEOPLASMS; GENE EXPRESSION REGULATION; GENETICS; NEOPLASM RECURRENCE, LOCAL; OBSERVER VARIATION; PATHOLOGY; PROGNOSIS; REPRODUCIBILITY; STANDARDS; TISSUE FIXATION;

COLONIC NEOPLASMS; DNA, COMPLEMENTARY; DNA, NEOPLASM; FORMALDEHYDE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; OBSERVER VARIATION; PARAFFIN EMBEDDING; PROGNOSIS; QUALITY CONTROL; REAGENT KITS, DIAGNOSTIC; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TISSUE FIXATION; TUMOR MARKERS, BIOLOGICAL;

EID: 84898547466     PISSN: 15412016     EISSN: 15334058     Source Type: Journal    
DOI: 10.1097/PDM.0000000000000031     Document Type: Article

References (28)

1. American Cancer Society. Cancer Facts and Figures 2013. Atlanta, GA: American Cancer Society; 2013.
2. Edge S, Byrd D, Compton C, et al. AJCC Cancer Staging Manual. 7th ed. New York, NY: Springer; 2010.
3. Benson AB III, Schrag D, Somerfield MR, et al. American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J Clin Oncol. 2004;22:3408-3419.
4. Gray R, Barnwell J, McConkey C, et al. Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study. Lancet. 2007;370:2020-2029.
5. Cutsem EV, Oliveira J. Primary colon cancer: ESMO clinical recommendations for diagnosis, adjuvant treatment and follow-up. Ann Oncol. 2009;20:49-50.
6. Grothey A, Gramont A, Sargent DJ. Disease-free survival in colon cancer: still relevant after all these years. J Clin Oncol. 2013;31:1-2.
7. Kennedy RD, Bylesjo M, Kerr P, et al. Development and Independent validation of a prognostic assay for stage II colon cancer using formalin-fixed paraffin-embedded tissue. J Clin Oncol. 2011;29:1-7.
8. CLSI. CLSI Document MM22. Microarrays for Diagnosis and Monitoring Infectious Diseases; Draft Guideline. Wayne, PA: Clinical and Laboratory Standards Institute; 2013.
9. Linnet K. Performance of Deming regression analysis in case of misspecified analytical error ratio in method comparison studies. Clin Chemistry. 1998;44:1024-1031.
10. NCCLS. NCCLS document EP21-A. Estimation of Total Analytical Error for Clinical Laboratory Methods; Approved Guideline. Wayne, PA: NCCLS; 2003.
11. Food and Drug Administration. Draft guidance for industry. Bioanalytical Method Validation. Rockville, MD: US Food and Drug Administration; 1999.
12. CLSI. CLSI document EP09-A2-IR. Method Comparison and Bias Estimation Using Patient Samples; Approved guideline-Second Edition (Interim Revision). Wayne, PA: Clinical and Laboratory Standards Institute; 2010.
13. NCCLS. NCCLS document EP17-A. Protocols for Determination of Limits of Detection and Limits of Quantitation; Approved Guideline. Wayne, PA: NCCLS; 2004.
14. OHRP. Guidance on Research Involving Coded Private Information or Biological Specimens, 2008. Available at http:// www.hhs.gov/ohrp/policy/ cdebiol.html. Accessed May 31, 2013.
15. Niedzwiecki D, Bertagnolli MM, Warren RS, et al. Documenting the natural history of patients with resected stage II adenocarcinoma of the colon after random assignment to adjuvant treatment with edrecolomab or observation: results from CALGB 9581. J Clin Oncol. 2011;29:3146-3152.
16. International Vocabulary of Metrology. Basic and General Concepts and Associated Terms (VIM). 3rd ed. Sevres, France: Joint Committee for Guides in Metrology (JCGM); 2008.
17. Deal AM, Pate VW, Rouby SE. ASAS Macro for Deming Regression-whitepaper publication. 2009. Available at http:// analytics.ncsu.edu/sesug/2009/CC014. Deal.pdf. Accessed May 31, 2013.
18. Manual: Universal Human Reference RNA, 2005. Available at http://www.chem-agilent.com/pdf/strata/740000.pdf. Accessed May 31, 2013.
19. Gangadhar T, Schilsky RL. Molecular markers to individualize adjuvant therapy for colon cancer. Nat Rev Clin Oncol. 2010;7: 318-325.
20. Harkin DP. Uncovering functionally relevant signaling pathways using microarray-based expression profiling. Oncologist. 2000;5: 501-507.
21. Schaeybroeck SV, Allen WL, Turkington RC, et al. Implementing prognostic and predictive biomarkers in CRC clinical trials. Nat Rev Clin Oncol. 2011;8:222-232.
22. Salazar R, Roepman P, Capella G, et al. Gene expression signature to improve prognosis prediction of stage II and II colorectal cancer. J Clin Oncol. 2011;29:17-24.
23. Lenehan PF, Boardman LA, Riegert-Johnson D, et al. Generation and external validation of a tumor-derived 5-gene prognostic signature for recurrence of lymph node-negative invasive colorectal carcinoma. Cancer. 2012;118:5234-5244.
24. Gray RG, Quirke P, Handley K, et al. Validation study of a quantitative multigene reverse transcriptase-polymerase chain reaction assay for assessment of recurrence risk in patients with stage II colon cancer. J Clin Oncol. 2011;29:4611-4619.
25. Bertucci F, Salas S, Eysteries S, et al. Gene expression profiling of colon cancer by DNA microarrays and correlation with histoclinical parameters. Oncogene. 2004;23:1377-1391.
26. Wang Y, Jatkoe T, Zhang Y, et al. Gene expression profiles and molecular markers to predict recurrence of Dukes' B colon cancer. J Clin Oncol. 2004;22:1564-1571.
27. Eschrich S, Yang I, Bloom G, et al. Molecular staging for survival prediction of colorectal cancer patients. J Clin Oncol. 2005;23: 3526-3535.
28. Arango D, Laiho P, Kokko A, et al. Gene expression profiling predicts recurrence in Dukes' C colorectal cancer. Gastroenterology. 2005;129:874-884.